期刊文献+

非特殊型浸润性乳腺癌HER-2检测方法的对比研究 被引量:6

Comparison of different methods for HER-2 status detection in non-special invasive breast carcinoma
下载PDF
导出
摘要 目的应用实时定量PCR技术(quantitive real-time PCR,q PCR)检测石蜡包埋非特殊型浸润性乳腺癌标本的HER-2表达状况,与免疫组织化学技术(immunohistochemistry,IHC)和荧光原位杂交技术(fluorescence in situ hybridization,FISH)相应检测结果进行比较,以验证q PCR技术检测HER-2方法的可靠性和实用性。方法采用FISH和q PCR技术对IHC检测结果分别为HER-2(0、1+、2+、3+)的乳腺癌标本各100例进行检测,用kappa检验分析三者的一致性。结果 100例HER-2(0)和HER-2(1+)的标本FISH和q PCR的检测结果均无扩增,符合率100%;IHC检测HER-2(2+)的标本,FISH和q PCR检测结果之间k=0.731(P<0.001),二者一致性强;IHC检测HER-2(3+)的标本,FISH与q PCR检测结果 k=0.634(P<0.001),二者具有较好的一致性,与IHC检测结果也具有较强的一致性。三者对乳腺癌患者的临床病理指标反应具有较好的一致性。结论 q PCR方法简便、实用、有效,检测乳腺癌HER-2基因状况可与FISH法互为补充。 Objective To compare quantitative polymerase chain reaction(qPCR) with immunohistochemistry(IHC) and fluorescence in situ hybridization(FISH) for the detection of HER-2 in non-special invasive breast carcinoma.Methods HER-2 expression levels in carcinoma tissue were detected using IHC,and the HER-2 gene expression levels were determined by FISH and qPCR.According to IHC results,all patients were divided into 4 groups[(HER-2(0),HER-2(1+),HER-2(2+) and HER-2(3+)]with 100 cases in each.The kappa test was used to measure the consistency among the results of IHC,FISH and qPCR.Results In HER-2(0) and HER-2(1+) groups,there were no differences between the results of qPCR and FISH.In HER-2(3+) group,a few discrepancies were found between qPCR and FISH[k=0.634(P〈0.001)].In HER-2(2+) group,the diagnostic consistency was good between qPCR and FISH[k=0.731(P〈0.001)].Using FISH test,there was consistency in correlation between HER-2 expression and clinicopathological parameters in the results of qPCR,FISH and IHC.Conclusion qPCR is a convenient,objective and efficient method,which may be used as an alternative to FISH,for the detection of HER-2 gene state of non-special invasive breast carcinoma.
出处 《分子诊断与治疗杂志》 2016年第5期308-315,共8页 Journal of Molecular Diagnostics and Therapy
基金 国家自然科学基金(81272420) 山东省自然科学基金(ZR2012HM085)
关键词 非特殊型浸润性乳腺癌 HER-2 IHC FISH qPCR Non-special invasive breast carcinoma HER-2 IHC FISH q PCR
  • 相关文献

参考文献21

  • 1Demonty G,Bernard-Marty C,Puglisi F,et al.Progress and new standards of care in the management of HER-2 positive breast cancer[J].Eur J Cancer,2007,43(3):497-509.
  • 2Mandusic V,Dimitrijevic B,Nikolic-Vukosavljevic D,et al.Different associations of estrogen receptorβisoforms,ERβ1 and ERβ2,expression levels with tumor size and survival in early-and late-onset breast cancer[J].Cancer Lett,2012,321(1):73-79.
  • 3Berghoff AS,Bago-Horvath Z,Dubsky P,et al.Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer[J].Breast J,2013,19(2):149-155.
  • 4Bayoudh L,Afrit M,Daldoul O,et al.Trastuzumab(herceptin)for the medical treatment of breast cancer[J].Tunis Med,2012,90(1):6-12.
  • 5Petersen ER,Srensen PD,Jakobsen EH,et al.Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer[J].Clin Chem Lab Med,2013,51(7):1483-1492.
  • 6Nistor A,Watson PH,Pettigrew N,et al.Real-time PCR complements immunohistochemistry in the deter mination of HER2/neu status in breast cancer[J].BMC Clin Pathol,2006,6:2-5.
  • 7Specht K,Richter T,Müller U,et al.Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue[J].Am J Pathol,2001,158(2):419-429.
  • 8Wolff AC,Hammond ME,Schwartz JN,et al.Recommendations for human epidermal growth factor receptor 2 Testing in Breast Cancer:American Society of Clinical Oncology/College of American Pathologists Guideline update[J].J Clin Oncol,2013,31(31):3997-4013.
  • 9乳腺癌HER2检测指南(2014版)[J].中华病理学杂志,2014,43(4):262-267. 被引量:295
  • 10Slamon DJ,Godolphin W,Jones LA,et al.Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer[J].Science,1989,244(4905):707-712.

二级参考文献20

  • 1张瑰红,施达仁,梁晓曼,侯景辉,康苏娅,朱卫东,李晓兵,邵云,陈丽荣,周燕.显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究[J].中华病理学杂志,2006,35(10):580-583. 被引量:29
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 3Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer [ J]. J Clin Oncol, 2007, 25 (33) :5287-5312.
  • 4Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Chnical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[ Jl. J Clin Oncol, 2007, 25 ( 1 ) : 118- 145.
  • 5Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth faetor reeeptor 2 testing in breast eaneer: American Society of Clinical Oneology/College of American Pathologists clinical practice guideline update[J]. J Clin Oneol, 2013, 31 (31) :3997-4013.
  • 6Hanna WM, Kwok K. Chromogenic in-situ hybridization:a viable ahernative to fluorescence in-situ hybridization in the HER2 testing algorithm[J]. Mod Pathol, 2006, 19(4) :481-487.
  • 7Park K, Han S, Kim JY, et al. Silver-enhanced in situ hybridization as an alternative to fluorescence in situ hybridization for assaying HER2 amplification in clinical breast cancer [ J ]. J Breast Cancer, 2011, 14(4) :276-282.
  • 8Haines GK 3rd, Wiley E, Susnik B, et al. HER2 in well differentiated breast cancer: is testing necessary? [ J ]. Breast Cancer Res Treat, 2008, 112(3) :551-556.
  • 9Zhu X, Lu Y, Lu H, et al. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer [J]. Hum Pathol, 2011,42(10) : 1499-1504.
  • 10Marchio C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer.9 A fluorescence in situ hybridization and microarray-based CGH analysis[ J]. J Pathol, 2009, 219( 1 ) : 16-24.

共引文献294

同被引文献49

引证文献6

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部